cryptotanshinone has been researched along with Acute Lymphoid Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Efferth, T; Klauck, SM; Wu, CF | 1 |
| Efferth, T; Klauck, SM; Seo, EJ; Wu, CF | 1 |
2 other study(ies) available for cryptotanshinone and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Anticancer activity of cryptotanshinone on acute lymphoblastic leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Adhesion; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Molecular Docking Simulation; NF-kappa B; Oligonucleotide Array Sequence Analysis; Phenanthrenes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reactive Oxygen Species; Signal Transduction | 2016 |
Cryptotanshinone deregulates unfolded protein response and eukaryotic initiation factor signaling in acute lymphoblastic leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Computational Biology; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factor-4A; Eukaryotic Initiation Factors; Humans; Molecular Docking Simulation; Pharmacogenetics; Phenanthrenes; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Messenger; Signal Transduction; Transcription Factor CHOP; Transcription Factors; Unfolded Protein Response | 2016 |